John Lambert
Fortuna: - $ al 31/05/2026
Fortuna: - $ al 31/05/2026
John M.
Lambert is currently Director at Defence Therapeutics Inc, starting in 2026.
Formerly, Dr. Lambert was Chief Scientific Officer & Executive VP-Research at ImmunoGen, Inc. from 2011 to 2015 and Assistant Professor-Pathology at Dana-Farber Cancer Institute, Inc. Education includes a doctorate from the University of Cambridge and an undergraduate degree from Christ's College (United Kingdom).
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 01/06/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| DEFENCE THERAPEUTICS INC. | Director/Miembro de la Junta | 01/06/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Provides treatment to cancer patients | Corporate Officer/Principal | - |
| IMMUNOGEN, INC. | Director Técnico/Científico/I+D | 05/01/2015 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
| Empresas privadas | 5 |
|---|---|
ImmunoGen, Inc.
ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Provides treatment to cancer patients | Health Services |
University of Cambridge
University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Christ's College (United Kingdom)
Christ's College (United Kingdom) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Defence Therapeutics Inc
Defence Therapeutics Inc Pharmaceuticals: MajorHealth Technology Engages in the research and development of anti-body drug conjugates | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.